Abstract
Purpose
A retrospective analysis was performed of preclinical and clinical data acquired during the evaluation of the estrogen receptor (ER) PET tracer 4-fluoro-11β-methoxy-16α-[18F]-fluoroestradiol (4FMFES) and its comparison with 16α-[18F]-fluoroestradiol (FES) in mice, rats, and humans with a focus on the brain uptake.
Procedures
Breast cancer tumor-bearing female BALB/c mice from a previous study and female Sprague-Dawley rats (control and ovariectomized) were imaged by 4FMFES or FES-PET imaging. Immediately after, low-dose CT was performed in the same bed position. Semi-quantitative analysis was conducted to extract %ID/g data. Small cohorts of mice and rats were imaged with 4FMFES in an ultra-high-resolution small animal PET scanner prototype (LabPET II). Rat brains were dissected and imaged separately with both PET and autoradiography. In parallel, 31 breast cancer patients were enrolled in a clinical phase II study to compare 4FMFES with FES for oncological assessment. Since the head was included in the field of view, brain uptake of discernable foci was measured and reported as SUVMax.
Results
Regardless of the species studied, 4FMFES and FES uptake were relatively uniform in most regions of the brain, except for bilateral foci at the base of the skull, at the midsection of the brain. Anatomical localization of the PET signal using CT image fusion indicates that the signal origins from the pituitary in all studied species. 4FMFES yielded lower pituitary uptake than FES in patients, but an inverse trend was observed in rodents. 4FMFES pituitary contrast was higher than FES in all assessed groups. High-resolution small animal imaging of the brain of rats and mice revealed a supplemental signal anterior to the pituitary, which is likely to be the medial preoptic area. Dissection data further confirmed those findings and revealed additional signals corresponding to the arcuate and ventromedial nuclei, along with the medial and cortical amygdala.
Conclusion
4FMFES allowed visualization of ER expression in the pituitary in humans and two different rodent species with better contrast than FES. Improvement in clinical spatial resolution might allow visualization and analysis of other ER-rich brain areas in humans. Further work is now possible to link 4FMFES pituitary uptake to cognitive functions.
Similar content being viewed by others
References
Muramatsu M, Inoue S (2000) Estrogen receptors: how do they control reproductive and nonreproductive functions? Biochem Biophys Res Commun 270:1–10
Shupnik MA (2002) Oestrogen receptors, receptor variants, and oestrogen actions in the hypothalamic-pituitary axis. J Neuroendocrinol 14:85–94
Snoeren EM, Antonio-Cabrera E, Spiteri T et al (2015) Role of oestrogen α receptors in sociosexual behaviour in female rats housed in a seminatural environment. J Neuroendocrinol 27(11):803–818
Balzer BW, Duke SA, Hawke CI, Steinbeck KS (2015) The effects of estradiol on mood and behavior in human female adolescents: a systematic review. Eur J Pediatr 174(3):289–298
Mott NN, Pak TR (2013) Estrogen signaling and the aging brain: context-dependent considerations for postmenopausal hormone therapy. ISRN Endocrinol 2013:814690
McCarrey AC, Resnick SM (2015) Postmenopausal hormone therapy and cognition. Horm Behav 74:167–172
Matyi JM, Rattinger GB, Schwartz S, Buhusi M, Tschanz JT (2019) Lifetime estrogen exposure and cognition in late life: the Cache County study. Menopause 26(12):1366–1374
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn C (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 278:1349–1356
Brinton RD, Yao J, Yin F, Mack WJ, Cadenas E (2015) Perimenopause as a neurological transition state. Nat Rev Endocrinol 11:393–405
Rocca WA, Grossardt BR, Shuster LT (2014) Oophorectomy, estrogen, and dementia: a 2014 update. Mol Cell Endocrinol 389:7–12
Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc E, Vaughan L, Robinson J, Rapp SR, Goveas JS, Wactawski-Wende J, Stefanick ML, Li W, Resnick SM, WHIMSY Study Group (2013) Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 173(15):1429–1436
Wharton W, Gleason CE, Dowling NM, Carlsson CM, Brinton EA, Santoro MN, Neal-Perry G, Taylor H, Naftolin F, Lobo RA, Merriam G, Manson JAE, Cedars MI, Miller VM, Black DM, Budoff M, Hodis HN, Harman SM, Asthana S (2014) The KEEPS-cognitive and affective study: baseline associations between vascular risk factors and cognition. J Alzheimers Dis 40(2):331–341
Humphreys GI, Ziegler YS, Nardulli AM (2014) 17β-estradiol modulates gene expression in the female mouse cerebral cortex. PLoS One 9(11):e111975
Mahfouz A, Lelieveldt BP, Grefhorst A et al (2016) Genome-wide coexpression of steroid receptors in the mouse brain: identifying signaling pathways and functionally coordinated regions. Proc Natl Acad Sci U S A 113(10):2738–2743
Shughrue PJ, Lane MV, Merchenthaler I (1997) Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol 388(4):507–525
Mitra SW, Hoskin E, Yudkovitz J, Pear L, Wilkinson HA, Hayashi S, Pfaff DW, Ogawa S, Rohrer SP, Schaeffer JM, McEwen BS, Alves SE (2003) Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. Endocrinology 144(5):2055–2067
Merchenthaler I, Lane MV, Numan S, Dellovade TL (2004) Distribution of estrogen receptor alpha and beta in the mouse central nervous system: in vivo autoradiographic and immunocytochemical analyses. J Comp Neurol 473(2):270–291
Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ (1984) Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 25(11):1212–1221
Seimbille Y, Rousseau J, Bénard F, Morin C, Ali H, Avvakumov G, Hammond GL, van Lier JE (2002) 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 67(9):765–775
Fowler AM, Chan SR, Sharp TL, Fettig NM, Zhou D, Dence CS, Carlson KE, Jeyakumar M, Katzenellenbogen JA, Schreiber RD, Welch MJ (2012) Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. J Nucl Med 53(7):1119–1126
Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA (2017) 18F-Fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: using an imaging biomarker to guide drug dosage in subsequent trials. Clin Cancer Res 23(12):3053–3060
Chae SY, Ahn SH, Kim SB, Han S, Lee SH, Oh SJ, Lee SJ, Kim HJ, Ko BS, Lee JW, Son BH, Kim J, Ahn JH, Jung KH, Kim JE, Kim SY, Choi WJ, Shin HJ, Gong G, Lee HS, Lee JB, Moon DH (2019) Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. Lancet Oncol 20(4):546–555
Pareto D, Alvarado M, Hanrahan SM, Biegon A (2004) In vivo occupancy of female rat brain estrogen receptors by 17beta-estradiol and tamoxifen. Neuroimage 23(3):1161–1167
Khayum MA, de Vries EF, Glaudemans AW, Dierckx RA, Doorduin J (2014) In vivo imaging of brain estrogen receptors in rats: a 16α-18F-fluoro-17β-estradiol PET study. J Nucl Med 55(3):481–487
Moresco RM, Casati R, Lucignani G, Carpinelli A, Schmidt K, Todde S, Colombo F, Fazio F (1995) Systemic and cerebral kinetics of 16 alpha [18F]fluoro-17 beta-estradiol: a ligand for the in vivo assessment of estrogen receptor binding parameters. J Cereb Blood Flow Metab 15(2):301–311
Paquette M, Phoenix S, Ouellet R, Langlois R, van Lier JE, Turcotte ÉE, Bénard F, Lecomte R (2013) Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model. Mol Imaging Biol 15(5):625–632
Paquette M, Lavallée É, Phoenix S, Ouellet R, Senta H, van Lier JE, Guérin B, Lecomte R, Turcotte ÉE (2018) Improved estrogen receptor assessment by PET using the novel radiotracer 18F-4FMFES in estrogen receptor-positive breast cancer patients: an ongoing phase II clinical trial. J Nucl Med 59(2):197–203
Gaudin E, Thibaudeau C, Arpin L et al (2017) Initial results of a truly pixelated APD-based PET scanner for high-resolution preclinical imaging. J Nucl Med 58(suppl 1):91
Lim JL, Zheng L, Berridge MS, Tewson TJ (1996) The use of 3-methoxymethyl-16-beta, 17-beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of [18F]-16α-fluoroestradiol. Nucl Med Biol 23:911–915
Seimbille Y, Ali H, van Lier JE (2002) Synthesis of 2,16α- and 4,16α-difluoroestradiols and their 11β-methoxy derivatives as potential estrogen receptor-binding radiopharmaceuticals. J Chem Soc Perkin Trans 5:657–663
Bergeron M, Cadorette J, Tétrault MA, Beaudoin JF, Leroux JD, Fontaine R, Lecomte R (2014) Imaging performance of LabPET APD-based digital PET scanners for pre-clinical research. Phys Med Biol 59(3):661–678
Selivanov VV, Picard Y, Cadorette J, Rodrigue S, Lecomte R (2000) Detector response models for statistical iterative image reconstruction in high resolution PET. IEEE Trans Nucl Sci 47(3):1168–1175
Mitchner NA, Garlick C, Ben-Jonathan N (1998) Cellular distribution and gene regulation of estrogen receptors alpha and beta in the rat pituitary gland. Endocrinology 139(9):3976–3983
Laflamme N, Nappi RE, Drolet G, Labrie C, Rivest S (1998) Expression and neuropeptidergic characterization of estrogen receptors (ERα and ERβ) throughout the rat brain: anatomical evidence of distinct roles of each subtype. J Neurobiol 36:357–378
Kanageswaran N, Nagel M, Scholz P, Mohrhardt J, Gisselmann G, Hatt H (2016) Modulatory effects of sex steroids progesterone and estradiol on odorant evoked responses in olfactory receptor neurons. PLoS One 2016;11(8):e0159640
Peterson LM, Kurland BF, Linka JM et al (2011) Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol 38:969–978
Yoo J, Dence CS, Sharp TL, Katzenellenbogen JA, Welch MJ (2005) Synthesis of an estrogen receptor-β selective radioligand: 5-[18F]fluoro-(2R*,3S*)-2,3-bis(4-hydroxyphenyl)pentanenitrile and comparison of in vivo distribution with 16α-[18F]Fluoro-17β-estradiol. J Med Chem 48:6366–6378
Antunes IF, van Waarde A, Dierckx RA et al (2017) Synthesis and evaluation of the estrogen receptor β-selective radioligand 2-18F-fluoro-6-(6-hydroxynaphthalen-2-yl)pyridin-3-ol: comparison with 16α-18F-fluoro-17β-estradiol. J Nucl Med 58(4):554–559
Lamichhane TR, Pangeni S, Paudel S, Lamichhane HP (2015) Age and gender related variations of pituitary gland size of healthy nepalese people using magnetic resonance imaging. Am J Biomed Eng 5(4):130–135
Cao D, Ma X, Zhang WJ, Xie Z (2017) Dissection and coronal slice preparation of developing mouse pituitary gland. J Vis Exp 16(129). https://doi.org/10.3791/56356
DuBray La Perle KM, Dintzis SM (2017) Endocrine system. In: Treuting PM, Dintzis SM, Montine KS (eds) Comparative anatomy and histology; a mouse. Elsevier, Rat and Human Atlas, pp 251–273
Catana C (2019) Development of dedicated brain PET imaging devices: recent advances and future perspectives. J Nucl Med 60(8):1044–1052
Watanabe M, Saito A, Isobe T, Ote K, Yamada R, Moriya T, Omura T (2017) Performance evaluation of a high-resolution brain PET scanner using four-layer MPPC DOI detectors. Phys Med Biol 62(17):7148–7166
Gaudin É, Toussaint M, Thibaudeau C, Paille M, Fontaine R, Lecomte R (2019) Performance simulation of an ultra-high resolution brain PET scanner using 1.2-mm pixel detectors. IEEE Trans Radiat Plasma Med Sci 3(3):334–342
Gaudin É, Toussaint M, Thibaudeau C et al (2019) Simulation studies of the SAVANT high resolution dedicated brain PET scanner using individually coupled APD detectors and DOI encoding. J Nucl Med 60(suppl 1):531
Funding
This project was indirectly funded by the Canadian Breast Cancer Foundation (CBCF) for the clinical portion, as well as the Natural Sciences and Engineering Research Council of Canada for the development of the scanners. The preclinical studies were carried out with the support of the Sherbrooke Molecular Imaging Center and the Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
RL is a co-founder and chief scientific officer of IR&T Inc. who was involved in the development of the prototype ultra-high-resolution PET scanner LabPET II. The other authors have no conflict of interest to declare regarding this paper or the results therein.
Ethical Approval
All animal procedures were approved by the Ethical Committee for Animal Care of the Université de Sherbrooke, in compliance with the policies and directives of the Canadian Council on Animal Care. Patients were retroactively analyzed from a previously reported phase II breast cancer clinical trial evaluating 4FMFES-PET, which was performed under the authority of Health Canada and approved by the Sherbrooke University Hospital Clinical Research Ethics Committee and Institutional Board.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Paquette, M., Phoenix, S., Lavallée, É. et al. Cross-Species Physiological Assessment of Brain Estrogen Receptor Expression Using 18F-FES and 18F-4FMFES PET Imaging. Mol Imaging Biol 22, 1403–1413 (2020). https://doi.org/10.1007/s11307-020-01520-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-020-01520-w